Merck June 24 announced that the Food and Drug Administration has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol.
Dulera is indicated for the treatment of asthma in patients 12 years of age and older, the Whitehouse Station, N.J.-based company said. It is not indicated for the relief of acute bronchospasm.
Merck said Dulera is expected to be available in retail pharmacies by the end of July.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.